Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Work In Process (2023 - 2025)

Historic Work In Process for Tarsus Pharmaceuticals (TARS) over the last 3 years, with Q3 2025 value amounting to $1.0 million.

  • Tarsus Pharmaceuticals' Work In Process fell 3712.31% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 3712.31%. This contributed to the annual value of $614000.0 for FY2024, which is 5663.27% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Work In Process of $1.0 million as of Q3 2025, which was down 3712.31% from $1.6 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Work In Process' 5-year high stood at $1.6 million during Q3 2024, with a 5-year trough of $392000.0 in Q4 2023.
  • Its 3-year average for Work In Process is $977125.0, with a median of $882500.0 in 2025.
  • Its Work In Process has fluctuated over the past 5 years, first soared by 5663.27% in 2024, then tumbled by 3712.31% in 2025.
  • Tarsus Pharmaceuticals' Work In Process (Quarter) stood at $392000.0 in 2023, then soared by 56.63% to $614000.0 in 2024, then skyrocketed by 63.03% to $1.0 million in 2025.
  • Its Work In Process stands at $1.0 million for Q3 2025, versus $1.6 million for Q2 2025 and $764000.0 for Q1 2025.